Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-Blind Study Evaluating the Efficacy and Safety of ABP 654 Compared With Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis

NCT04607980 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT04607980
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04607980 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-Blind Study Evaluating the Efficacy and Safety of ABP 654 Compared With Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
November 11, 2020
Completion date
June 3, 2022
Enrollment
563 (actual)
Sites
84

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis